Nuevas formas cristalinas de n- (3- (2- (2-hidroxietoxia) -6-morfolinopiridin-4-yl) -4-methvlfenil) -2 (trifluorometil) isonicotinamida como inhibidores de la raf para el tratamiento del cáncer
La presente invención se refiere a formas cristalinas de N-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida, y a procesos para su preparación. Además, la invención se refiere a una composición farmacéutica que comprende dichas formas cristalinas de N-(3...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | spa |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | HARLACHER, Cornelius Stephen WAYKOLE, Liladhar Murlidhar LI, Zaixing |
| description | La presente invención se refiere a formas cristalinas de N-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida, y a procesos para su preparación. Además, la invención se refiere a una composición farmacéutica que comprende dichas formas cristalinas de N-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida, y por lo menos un excipiente farmacéuticamente aceptable. La composición farmacéutica de la presente invención puede usarse como un medicamento, en particular, para el tratamiento de cáncer.
The present invention relates to crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinanmide and to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-trifluoromethyl)isonicotinamide, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of cancers. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CL2021002963A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CL2021002963A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CL2021002963A13</originalsourceid><addsrcrecordid>eNqNjUFKBEEMRXvjQtQ7BNyMi4Ke6mHApQyKC3HlfohVKTpQVWlSNYMex6voxcwMHsDFz0_yH_zL4fv1QEdskESLWVBuHTNX2yNBdbCaTP6smaPKB1O3gXfgtq6IJjFaFlaOXN3GfWZLNq5Qn485UeXT7WHVlVM-iIolpx83qRykW1XhiBCkCHCd-Z2jKJ3rM4JiggUVgTJ0xW4w1S6WZgg_XzWQXg8XCXOjmz-_Gm6fHt92z44W2VNbMFClvt-9-NGvx9Hfb6eH9fQ_6hfSjF9X</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Nuevas formas cristalinas de n- (3- (2- (2-hidroxietoxia) -6-morfolinopiridin-4-yl) -4-methvlfenil) -2 (trifluorometil) isonicotinamida como inhibidores de la raf para el tratamiento del cáncer</title><source>esp@cenet</source><creator>HARLACHER, Cornelius Stephen ; WAYKOLE, Liladhar Murlidhar ; LI, Zaixing</creator><creatorcontrib>HARLACHER, Cornelius Stephen ; WAYKOLE, Liladhar Murlidhar ; LI, Zaixing</creatorcontrib><description>La presente invención se refiere a formas cristalinas de N-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida, y a procesos para su preparación. Además, la invención se refiere a una composición farmacéutica que comprende dichas formas cristalinas de N-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida, y por lo menos un excipiente farmacéuticamente aceptable. La composición farmacéutica de la presente invención puede usarse como un medicamento, en particular, para el tratamiento de cáncer.
The present invention relates to crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinanmide and to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-trifluoromethyl)isonicotinamide, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of cancers.</description><language>spa</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220909&DB=EPODOC&CC=CL&NR=2021002963A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220909&DB=EPODOC&CC=CL&NR=2021002963A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HARLACHER, Cornelius Stephen</creatorcontrib><creatorcontrib>WAYKOLE, Liladhar Murlidhar</creatorcontrib><creatorcontrib>LI, Zaixing</creatorcontrib><title>Nuevas formas cristalinas de n- (3- (2- (2-hidroxietoxia) -6-morfolinopiridin-4-yl) -4-methvlfenil) -2 (trifluorometil) isonicotinamida como inhibidores de la raf para el tratamiento del cáncer</title><description>La presente invención se refiere a formas cristalinas de N-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida, y a procesos para su preparación. Además, la invención se refiere a una composición farmacéutica que comprende dichas formas cristalinas de N-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida, y por lo menos un excipiente farmacéuticamente aceptable. La composición farmacéutica de la presente invención puede usarse como un medicamento, en particular, para el tratamiento de cáncer.
The present invention relates to crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinanmide and to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-trifluoromethyl)isonicotinamide, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of cancers.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjUFKBEEMRXvjQtQ7BNyMi4Ke6mHApQyKC3HlfohVKTpQVWlSNYMex6voxcwMHsDFz0_yH_zL4fv1QEdskESLWVBuHTNX2yNBdbCaTP6smaPKB1O3gXfgtq6IJjFaFlaOXN3GfWZLNq5Qn485UeXT7WHVlVM-iIolpx83qRykW1XhiBCkCHCd-Z2jKJ3rM4JiggUVgTJ0xW4w1S6WZgg_XzWQXg8XCXOjmz-_Gm6fHt92z44W2VNbMFClvt-9-NGvx9Hfb6eH9fQ_6hfSjF9X</recordid><startdate>20220909</startdate><enddate>20220909</enddate><creator>HARLACHER, Cornelius Stephen</creator><creator>WAYKOLE, Liladhar Murlidhar</creator><creator>LI, Zaixing</creator><scope>EVB</scope></search><sort><creationdate>20220909</creationdate><title>Nuevas formas cristalinas de n- (3- (2- (2-hidroxietoxia) -6-morfolinopiridin-4-yl) -4-methvlfenil) -2 (trifluorometil) isonicotinamida como inhibidores de la raf para el tratamiento del cáncer</title><author>HARLACHER, Cornelius Stephen ; WAYKOLE, Liladhar Murlidhar ; LI, Zaixing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CL2021002963A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>spa</language><creationdate>2022</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>HARLACHER, Cornelius Stephen</creatorcontrib><creatorcontrib>WAYKOLE, Liladhar Murlidhar</creatorcontrib><creatorcontrib>LI, Zaixing</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HARLACHER, Cornelius Stephen</au><au>WAYKOLE, Liladhar Murlidhar</au><au>LI, Zaixing</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Nuevas formas cristalinas de n- (3- (2- (2-hidroxietoxia) -6-morfolinopiridin-4-yl) -4-methvlfenil) -2 (trifluorometil) isonicotinamida como inhibidores de la raf para el tratamiento del cáncer</title><date>2022-09-09</date><risdate>2022</risdate><abstract>La presente invención se refiere a formas cristalinas de N-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida, y a procesos para su preparación. Además, la invención se refiere a una composición farmacéutica que comprende dichas formas cristalinas de N-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida, y por lo menos un excipiente farmacéuticamente aceptable. La composición farmacéutica de la presente invención puede usarse como un medicamento, en particular, para el tratamiento de cáncer.
The present invention relates to crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinanmide and to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-trifluoromethyl)isonicotinamide, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of cancers.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | spa |
| recordid | cdi_epo_espacenet_CL2021002963A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Nuevas formas cristalinas de n- (3- (2- (2-hidroxietoxia) -6-morfolinopiridin-4-yl) -4-methvlfenil) -2 (trifluorometil) isonicotinamida como inhibidores de la raf para el tratamiento del cáncer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T23%3A41%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HARLACHER,%20Cornelius%20Stephen&rft.date=2022-09-09&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECL2021002963A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |